Why the study?
To address the most important and controversial issues regarding the use of fixed-dose combination drugs in primary and secondary prevention of cardiovascular disease.
What is the position of Russian medical societies on the use of fixed-dose combination drugs in the primary and secondary prevention of cardiovascular disease?
What is the position of Russian medical societies on the use of fixed-dose combination drugs in the primary and secondary prevention of cardiovascular disease?
This position paper outlines the consensus of multiple Russian medical societies on the use of fixed-dose combination drugs for cardiovascular disease prevention.
Answers are grounded in this paper and cite their sources.
Guides Russian clinicians on fixed-dose combinations for CVD prevention; extends global evidence with multi-society consensus.
The paper describes the position of of the Russian Society of Cardiology, the Russian Society for the Prevention of Noncommunicable Diseases, the Russian Scientific Medical Society of Internal Medicine, the Russian Association of Endocrinologists, the Association of Clinical Pharmacologists, the Eurasian Association of Internal Medicine, the Russian Association of Gerontologists and Geriatricians on the most important and controversial issues of the use of fixed-dose combination drugs in the primary and secondary prevention of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Arutyunov et al. (2024) conducted a review in Cardiovascular disease. Fixed-dose combination drugs was evaluated. Fixed-dose combination drugs for the primary and secondary prevention of cardiovascular disease are the subject of this position paper detailing recommendations from multiple Russian medical societies.
Synapse has enriched 10 related papers. Consider them for comparative context: